miR-203a-3p通过靶向PRMT5抑制胃癌细胞增殖

目的:探讨miR-203a-3p在胃癌中的表达及其对胃癌细胞增殖的影响.方法:收集胃癌组织标本44例,采用Real-time PCR方法检测胃癌组织标本中miR-203a-3p的表达,并分析其表达水平与临床病理参数的关系;生物信息学预测miR-203a-3p的靶基因,并采用荧光素酶报告基因实验进行验证;免疫组化检测胃癌组织标本中PRMT5的表达情况,分析其表达水平与miR-203a-3p表达的相关性;利用脂质体介导的瞬时转染方法过表达miR-203a-3p或同时过表达miR-203a-3p和PRMT5,并通过CCK-8实验检测胃癌细胞的增殖情况.结果:胃癌组织中miR-203a-3p的表达水平与正常组织对照相比显著降低(P<0.01),并且miR-203a-3p的表达水平与肿瘤细胞的分化程度显著相关;荧光素酶报告基因实验证实miR-203a-3p可以直接结合在PRMT5 3'-UTR上,即PRMT5是miR-203a-3p的直接靶基因;在胃癌组织标本中,PRMT5表达水平显著高于正常组织对照(P<0.01),并且其表达水平与miR-203a-3p表达呈显著负相关(r=-0.4124,P<0.01);过表达miR-203a-3p后,胃癌BGC823细胞的增殖能力显著低于miR-NC对照组(P<0.01),并且,"挽救"实验表明在过表达miR-203a-3p的细胞中同时过表达PRMT5后会部分恢复miR-203a-3p对细胞增殖的抑制(P<0.01).结论:miR-203a-3p可通过下调靶基因PRMT5的表达,进而抑制胃癌细胞增殖.因此,miR-203a-3p可作为胃癌疾病临床治疗的潜在靶点.     

幽门螺杆菌感染诱导微小RNA?181c对胃癌细胞增殖和侵袭的影响

目的探讨幽门螺杆菌(Hp)感染诱导微小RNA-181c(miR-181c)对胃癌细胞增殖、侵袭和迁移的影响。方法采用实时定量PCR(QPCR)检测Hp感染人正常胃黏膜GES-1细胞和胃癌细胞(BGC-823、SGC-7901、AGS)的miR-181c水平。采用脂质体向SGC-7901细胞转染miR-181c抑制物(Inhibitor组)或阴性对照序列(NC组),另取未转染的细胞为对照组;转染48 h后采用QPCR检测miR-181c水平,活细胞计数(CCK-8)法、划痕实验和Transwell小室实验检测细胞增殖活力、划痕愈合率和穿膜细胞数以评估细胞增殖、迁移和侵袭能力,QPCR和Western blotting检测Bcl-2、基质金属蛋白酶(MMP)-9和神经型钙黏蛋白(N-cad)水平。结果QPCR检测结果显示Hp感染后各细胞的miR-181水平较感染前均升高(P<0.05),GES-1、BGC-823、SGC-7901和AGS细胞Hp感染后的miR-181c水平分别为感染前的4.37、1.63、3.25和2.09倍。与对照组和NC组相比,Inhibitor组SGC-7901细胞的miR-181c水平和转染48、72 h后的增殖活力降低(P<0.05);Inhibitor组SGC-7901细胞的划痕愈合率和穿膜细胞数量分别为(21.679±3.762)%和(128.056±21.463)个,低于对照组的(65.004±2.309)%和(325.07±34.082)个及NC组的(65.675±2.914)%和(328.035±31.391)个,差异有统计学意义(P<0.05);与对照组和NC组相比,Inhibitor组的Bcl-2、MMP-9和N-cad水平均降低(P<0.05)。对照组和NC组上述指标的差异无统计学意义(P>0.05)。结论Hp感染可升高胃癌细胞的miR-181c水平,下调该miR-181c水平对增殖、侵袭和迁移具有明显抑制作用,为Hp感染的胃癌治疗提供了新的靶点。     

Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients

A positive family history is an increased risk factor for gastric cancer within family members, and one of the possible causes of this is the intrafamilial clustering of Helicobacter pylori infection. Our study examined the prevalence of H. pylori infection, serum antibodies to CagA and VacA and atrophic gastritis and/or intestinal metaplasia in the offspring or siblings of gastric cancer patients. A total of 726 subjects included 300 relatives of 300 separate gastric cancer patients and 426 controls. All subjects underwent upper gastrointestinal endoscopic examination with a rapid urease test. Blood samples were obtained to test for the presence of serum antibodies to the CagA and VacA proteins of H. pylori. The prevalence of H. pylori infection was higher in relatives of cancer patients (75.3%) than in controls (60.1%), and the adjusted odds ratio was 2.1 (95% CI 1.5-2.9). When either siblings or 2 or more family members were gastric cancer patients, the prevalence of H. pylori infection was much higher compared to the prevalence in controls. There was no specific relationship between CagA and VacA, and H. pylori infection. Atrophic gastritis and/or intestinal metaplasia were more frequently found in H. pylori-infected relatives of cancer patients (26.1%) than in H. pylori-infected controls (12.9%). These results strongly support a role for H. pylori infection in familial aggregation of gastric cancer. The prophylactic eradication of H. pylori infection in the offspring or siblings of gastric cancer patients may be clinically beneficial.     

Epidemiology of Helicobacter pylori and gastric cancer

Findings in epidemiological studies of the relationship between Helicobacter pylori and gastric cancer have been inconsistent: many studies have yielded a positive relationship, whereas several studies have shown no relationship. The inconsistency arises because of the occurrence of seroreversion during the period between the time that H. pylori exerts a carcinogenic effect and the time of blood sampling. When this seroreversion is taken into account, there is an epidemiologically positive association between H. pylori status and the risk for gastric cancer. In addition to the epidemiological evidence, experimental studies using Mongolian gerbils have shown that H. pylori infection elevates the risk for gastric cancer. It is concluded that H. pylori is a causal factor for gastric cancer. In the creation of preventive strategies against gastric cancer by the eradication of H. pylori, determination of the time at which H. pylori plays a role as a carcinogen is important. Three hypotheses have been proposed in regard to this timing: that H. pylori infection in childhood or the teenage years acts as a factor that produces precancerous lesions with irreversible damage in the gastric mucosa, that in adulthood it acts as an initiator, and also in adulthood, that it acts as a promoter. As these hypotheses are not mutually exclusive, the extent to which each hypothesis plays a part in explaining gastric carcinogenesis should be evaluated. Only a small proportion of subjects infected with H. pylori have gastric cancer during their lifetime. Interleukin-1 polymorphism, a host factor, and CagA, a virulence factor of H. pylori, are suspected to be risk factors for gastric cancer in subjects with H. pylori infection. Dietary factors, especially vitamin C, and patterns of precancerous lesions also seem to influence the relationship between H. pylori and gastric cancer. H. pylori seems to reduce the risk for esophageal and for some gastric cardia adenocarcinomas. This finding, as well as determination of the time at which H. pylori exerts this preventive effect, should be considered in the creation of preventive strategies against gastric cancer that target the eradication of H. pylori. Received: June 1, 2001 / Accepted: October 16, 2001     

miR-203a通过靶向抑制CDK6调控膀胱癌细胞增殖及放射敏感性

目的:探讨miR-203a在膀胱癌(BC)细胞系(RT-112、T24、5637、UM-UC-3细胞)中的表达及对细胞增殖及放射敏感性的影响。方法:将miR-203a mimics、miR-203a inhibitor、CDK6 siRNA、CDK6表达质粒及相应阴性对照(NC)转染入BC细胞中。实时荧光定量PCR检测...     

Severe atrophic gastritis with Helicobacter pylori infection and gastric cancer

Background. We conducted a case-control study to evaluate whether patients with severe gastric atrophy (indicated by serum pepsinogen concentration) have a high risk of gastric cancer. Methods. At the time of diagnosis of gastric cancer, sera from 301 patients (cases) and 602 sex- and age-matched cancer-free individuals (controls) were tested for the presence of anti-Helicobacter pylori IgG antibody (HM-CAP enzyme-linked immunoassay [ELISA] kit; Kyowa Medix, Tokyo, Japan) and serum pepsinogen (PG) levels (PG I and II Riabead Kits; Dainabot, Tokyo, Japan). We defined positivity for pepsinogen a pepsinogen I concentration of less than 70 ng/mL and a PG I/II ratio of less than 3.0. We categorized the subjects according to serum pepsinogen levels and anti-Helicobacter pylori IgG antibody, creating four categories. Results. Of the 301 cancer cases, 177 had positive serum pepsinogen levels, and 172 were positive for anti-Helicobacter pylori IgG antibody. The category in which subjects had positive serum pepsinogen levels and were negative for anti-Helicobacter pylori IgG antibody had the highest proportion (76.9%) of individuals with gastric cancer and the highest odds ratio (4.20) of the four categories. The odds ratios were 2.55 (95% confidence interval; 1.92–3.88) for positive serum pepsinogen levels and 0.93 (95% confidence interval; 0.63–1.27) for positive anti-Helicobacter pylori IgG antibody. Conclusion. These results suggest that patients with positive serum pepsinogen levels who are negative for IgG antibody to Helicobacter pylori, constitute a high-risk group for gastric cancer. Helicobacter pylori infection is associated with the development of gastric cancer by providing a suitable environment i.e., severe gastric atrophy, for carcinogenesis of the gastric mucosa. Received for publication on Mar. 20, 1998; accepted on Aug. 20, 1998     

Global burden of gastric cancer attributable to Helicobacter pylori

We previously estimated that 660,000 cases of cancer in the year 2008 were attributable to the bacterium Helicobacter pylori (H. pylori), corresponding to 5.2% of the 12.7 million total cancer cases that occurred worldwide. In recent years, evidence has accumulated that immunoblot (western blot) is more sensitive for detection of anti‐H. pylori antibodies than ELISA, the detection method used in our previous analysis. The purpose of this short report is to update the attributable fraction (AF) estimate for H. pylori after briefly reviewing new evidence, and to reassess the global burden of cancer attributable to H. pylori. We therefore reviewed the literature for studies comparing the risk of developing non‐cardia gastric cancer (NCGC) in cases and controls, using both ELISA and multiple antigen immunoblot for detection of H. pylori. The results from prospective studies were combined, and the new pooled estimates were applied to the calculation of the AF for H. pylori in NCGC, then to the burden of infection‐related cancers worldwide. Using the immunoblot‐based data, the worldwide AF for H. pylori in NCGC increased from 74.7% to 89.0%. This implies approximately 120,000 additional cases of NCGC attributable to H. pylori infection for a total of around 780,000 cases (6.2% instead of 5.2% of all cancers). These updated estimates reinforce the role of H. pylori as a major cause of cancer.     

Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer

Overexpression of cyclooxygenase (COX)-2 has been implicated in the development of cancer. This study aimed to evaluate the relationship between genetic variants in COX-2 promoter interacting with Helicobacter pylori and the susceptibility to gastric cancer (GC). Three COX-2 polymorphisms -1290A>G (rs689465), -1195G>A (rs689466), and -765G>C (rs20417) were genotyped in 323 GC patients and 944 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression model. In GC patients, the ORs were 2.33 (95% CI = 1.50-3.63) and 2.70 (95% CI = 1.68-4.33) for -1195AA and -765CG genotype carriers, respectively. Haplotype analysis showed all -1195A allele-containing haplotypes, except G(-1290)-A(-1195)-G(-765), were associated with increased risk for GC, compared with the A(-1290)-G(-1195)-G(-765) haplotype. Moreover, significant multiplicative and additive interactions were observed between H. pylori infection and all these three polymorphisms, and H. pylori-infected subjects carrying the variant allele of -1290A>G, -1195G>A, or -765G>C had increased risk of GC compared with non-H. pylori-infected subjects with wild-type allele (OR = 4.10, 95% CI = 1.90-8.83; OR = 3.46, 95% CI = 1.31-9.11; and OR = 3.32, 95% = 1.27-8.73, respectively). Our results suggested that the COX-2 promoter polymorphisms were associated with increased risk of GC, especially interacting with H. pylori infection.     

Helicobacter pylori infection and gastric cancer: facing the enigmas

At an individual level Helicobacter pylori was associated with the occurrence of gastric cancer but in some African and Asian countries its prevalence runs with low gastric cancer rates, the so-called African and Asian enigmas. We assessed whether the association between gastric cancer and H. pylori prevalence at an area level is modified by the level of exposure to fruits and vegetables, alcohol or tobacco. Regression models were fitted to data from 58 countries using as dependent variable log transformed gastric cancer rates and as independent covariables the H. pylori prevalence, fruits and vegetables consumption, cigarette smoking, alcohol intake and interaction terms. The levels of alcohol consumption or cigarette smoking modified the association between gastric cancer and H. pylori infection. Models including H. pylori prevalence, alcohol consumption, cigarette smoking and the interaction terms H. pylori x alcohol or H. pylori x tobacco were used to compute gastric cancer incidence multiplying regression coefficients by a H. pylori prevalence of 85% (the approximate median in African countries) and the median figures observed in each continent for alcohol and tobacco availability. The expected gastric cancer incidence per 100,000 would be 5.7 assuming the alcohol and tobacco availability in African countries, 7.0 in Asia and Oceania, 16.0 in America and 26.0 in Europe. The interaction between H. pylori and cigarette or alcohol consumption may contribute to further explain the international variation in gastric cancer and the so-called African and Asian enigmas.     

S期激酶相关蛋白2在幽门螺杆菌L型致胃癌中的作用

目的：研究S期激酶相关蛋白2（S-phase kinase associated protein 2,Skp2）在幽门螺杆菌L型（Helicobacter pylori L-form,Hp-L型）感染致胃癌中所起的作用。方法：将胃癌BGC-823细胞与Hp-L型以不同比例共培养,在倒置显微镜下观察细胞形态学变化,并应用原位杂交和免疫组化分别检测Skp2 mRNA和蛋白在胃癌BGC-823细胞中的表达情况。同时收集慢性萎缩性胃炎（CAG）、胃肠腺化生（GIM）、胃不典型增生（GED）、胃癌（GCa）标本各40例,以40例轻度慢性浅表性胃炎（CSG）作为对照。应用革兰染色和免疫组化检测Hp-L型在上述组织中的感染情况;并进一步检测Hp-L型阳性组织中Skp2 mRNA和蛋白的表达情况。结果：Hp-L型作用BGC-823细胞后,倒置显微镜观察到细胞分裂增多,出现明显的生长加速现象;原位杂交和免疫组化检测发现BGC-823细胞中Skp2 mRNA和蛋白表达阳性率随细菌浓度的增加和作用时间的延长而逐渐增加（P〈0.05）。Hp-L型阳性组织中的Skp2mRNA和蛋白的表达阳性率按CAG、GIM、GED、GCa的顺序逐渐增加,但仅GCa组与CSG组间的差异具有统计学意义（P〈0.05）。结论：Skp2在Hp-L型感染的胃癌前病变及胃癌中均明显升高,提示其在胃癌的发生及发展中起着重要作用。     

幽门螺杆菌根除后胃癌发病的相关因素

胃癌是常见癌症之一.幽门螺杆菌感染是胃癌发生的主要致病因素.根除幽门螺杆菌可明显降低胃癌的发病率.但仍有部分患者在幽门螺杆菌根除后仍进展为胃癌.因此,早期识别幽门螺杆菌根除后的胃癌高危人群是一种经济、有效的胃癌预防手段.本文就目前报道的可预示幽门螺杆菌根除后原发性胃癌发病的相关因素及可能影响除菌后胃癌发病风险的药物进行...     

Risk of gastric cancer among smokers infected with Helicobacter pylori

Infection with the gastric bacterium Helicobacter pylori (in particular infection with CagA-positive strains) and smoking have been identified as risk factors for the development of gastric cancer. Both risk factors are typically acquired early in life and prevail over decades if not for life. We assessed the individual and joint impact of both risk factors on gastric cancer risk in a population-based case-control study from Germany including 71 patients with histologically verified gastric cancer and 363 patients with colorectal cancer who served as controls. Information on smoking and potential confounding factors was collected by standardized interviews. H. pylori infection was measured serologically by immunoglobulin G antibody titers against H. pylori. In addition, antibodies against the CagA antigen were determined by Western blot. Twenty-seven percent of cases compared with 15% of controls were smokers, and 43% of cases compared with 23% of controls were infected with CagA-positive H. pylori strains. After control for potential confounders, the relative risk of gastric cancer was 2.6 (95% CI 1.2-5.7) for nonsmoking subjects with CagA-positive H. pylori infections and 7.2 (95% CI 2.2-23.6) for smoking subjects with CagA-positive H. pylori infections compared with subjects without these risk factors. The corresponding relative risks for noncardia gastric cancer were 6.1 ( 95% CI 2.3-16.5) and 16.6 (95% CI 4.3-64.2). We conclude that smoking subjects with CagA-positive H. pylori infections have a strongly increased risk of gastric cancer and may be an important group for targeting efforts of prevention and early detection.     

幽门螺杆菌感染与胃癌发生发展及预后的相关性研究

目的探讨胃癌患者幽门螺杆菌(H.pylori,HP)的感染与其临床病理参数和预后的关系,以及在胃癌发生、发展及预后中的作用。方法应用实时荧光定量PCR的相对定量法,检测2004-01-01-2007-12-31石河子大学医学院第一附属医院病理科存档的石蜡包埋胃癌组织标本118例及其32例相应癌旁组织的HP相对感染量。应用SPSS 17.0软件,采用非参数检验Mann-Whitney U和Kruskal-Wallis H检验以及Log-rank检验等多种统计学分析方法。结果118例胃癌组织的HP相对感染量为0.02~26.76,平均为8.73±6.50,32例相应癌旁组织为0.29~8.06,平均为4.28±2.53。胃癌组织中HP相对感染量与患者年龄、性别、组织学分型、分化程度及有无远处转移无关,P>0.05;与浸润深度(P=0.001)、淋巴结转移(P=0.005)和临床分期(P=0.005)相关;在同一胃癌患者中,癌组织HP相对感染量显著高于癌旁组织,P<0.001;HP相对感染量<1、1相似文献   

Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer

We conducted a longitudinal cohort study to determine the association of Helicobacter pylori infection and the progression of chronic atrophic gastritis (CAG) with gastric cancer. A cohort of 4655 healthy asymptomatic subjects was followed for a mean period of 7.7 years. H. pylori infection was established by serum specific antibodies and the presence of CAG was confirmed by serum pepsinogen. During the follow-up period, 45 gastric cancer cases were detected (incidence rate, 126/100000 person-years). A univariate analysis after adjustment for age showed that both H. pylori and CAG were significantly associated with gastric cancer. To clarify the interaction between H. pylori and CAG, an analysis stratified by H. pylori- and CAG-status was performed. No cancer developed in the H. pylori(-)/CAG(-) group during the study period. This supports the theory that it is quite rare for any type of gastric cancer to develop in an H. pylori-free healthy stomach. With the progression of H. pylori-induced gastritis, the risk of gastric cancer increased in a stepwise fashion from CAG-free gastritis [H. pylori(+)/CAG(-) group] (HR=7.13, 95%CI=0.95-53.33) to CAG [H. pylori(+)/CAG(+) group] (HR=14.85, 95%CI=1.96-107.7) and finally to severe CAG with extensive intestinal metaplasia [H. pylori(-)/CAG(+) group] (HR=61.85, 95%CI=5.6-682.64) in which loss of H. pylori from the stomach is observed. Therefore, it is probable that H. pylori alone is not directly associated with stomach carcinogenesis. Instead, H. pylori appears to influence stomach carcinogenesis through the development of CAG. The observed positive correlation between the extent of H. pylori-induced gastritis and the development of cancer was strong, especially for the intestinal type. These results are compelling evidence that severe gastritis with extensive intestinal metaplasia is a major risk factor for gastric cancer, and they confirm the previously described model of stomach carcinogenesis: the gastritis-metaplasia-carcinoma sequence.     

miR-27b通过c-MET抑制胃癌细胞的生长、增殖及侵袭转移

目的:找出调控胃癌细胞c-MET的miRNA,研究该miRNA能否通过c-MET抑制胃癌细胞的生长、增殖及侵袭转移。方法:预测软件筛选出可能调节胃癌c-MET的miRNA。荧光定量PCR检测胃癌细胞株(N87、MKN45、AGS)及正常胃黏膜细胞(GES1)中该miRNA的表达水平。过表达miRNA后检测胃癌细胞株AGS中c-MET的表达水平,选择对c-MET抑制最强的miRNA行双荧光素酶实验。平板克隆及Transwell实验检测过表达该miRNA后胃癌细胞的生长、增殖及侵袭转移能力,过表达c-MET后再次检测胃癌细胞的生长、增殖及侵袭转移能力。结果:预测软件显示miR-34a、miR-27b及miR-31可能调节胃癌cMET表达。miR-34a、miR-27b及miR-31在胃癌细胞株中表达较正常胃黏膜明显降低(P<0.05)。Western bolt显示miR-27b对c-MET的抑制能力最强。双荧光素酶实验同样证实了c-MET是miR-27b的直接作用靶点。平板克隆及Transwell实验显示过表达miR-27b能抑制胃癌细胞的生长、增殖及侵袭转移能力,而过表达c-MET后能恢复胃癌细胞的生长、增殖及侵袭转移能力。结论:miR-27b能作用于c-MET 3’UTR端从而抑制c-MET的表达,并能通过c-MET抑制胃癌细胞的生长、增殖及侵袭转移。     

幽门螺杆菌感染对晚期胃癌自体DC-CIK维持治疗的影响

目的：对比幽门螺杆菌（Helicobacter pylori,Hp）感染阴性和阳性的晚期胃癌患者接受自体树突状细胞联合细胞因子诱导的杀伤（dendritic cells-cytokine induced killer,DC-CIK）细胞维持治疗的疗效差异。方法：收集2010年6月至2012年6月中国人民解放军第174医院肿瘤中心收治的72例晚期胃癌患者,年龄29~90岁,中位年龄56岁,通过胃镜检查进行胃癌确诊并检测Hp,分为Hp阳性组（45例）及Hp阴性组（27例）,在接受手术或/和放化疗后,接受2疗程自体DC-CIK维持治疗,比较两组外周血培养的DC分化成熟情况及临床疗效差异。结果： 两组DC成熟过程形态变化无差异;Hp阳性组DC表面分子CD83、CD86表达显著高于Hp阴性组（P<0.01）,两组间HIA-DR表达无明显差异（P>0.05）。Hp阳性组治疗后生活质量评分（KPS）、外周血T细胞亚群（CD3+、CD4+、CD8+）比例较治疗前显著提高（P<0.05）,肿瘤标志物（CEA、CA199、CA724）表达较治疗前下降（P<0.05）。Hp阴性组治疗后肿瘤标志物表达、外周血T淋巴细胞比例较治疗前显著降低（P<005）,KPS评分较治疗前无明显变化（P>0.05）。Hp阳性组治疗后KPS评分、CEA和CA199表达以及CD3+和CD4+T细胞数量等的改善均优于Hp阴性组（P<0.05）,但瘤体稳定率、CA724、CD8+T细胞比例无显著差异（P>0.05）。共随访2年,阳性组患者中位生存期为12.64个月,长于阴性组的11.42个月（P<0.05）。结论： 携带Hp抗原信息的DC疫苗协同CIK治疗能够提高Hp感染的晚期胃癌患者的自身免疫功能,达到稳定瘤体、改善生活质量、延长生存期的目的。     

MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2

Several microRNAs (miRNA) have been implicated in H. pylori related gastric cancer (GC). However, the molecular mechanism of miRNAs in gastric cancer has not been fully understood. In this study, we reported that miR-101 is significantly down-regulated in H. pylori positive tissues and cells and in tumor tissues with important functional consequences. Ectopic expression of miR-101 dramatically suppressed cell proliferation and colony formation by inducing G1-phase cell-cycle arrest. We found that miR-101 strongly reduced the expression of SOCS2 oncogene in GC cells. Similar to the restoring miR-26 expression, SOCS2 down-regulation inhibited cell growth and cell-cycle progression, whereas SOCS2 over-expression rescued the suppressive effect of miR-101. Mechanistic investigations revealed that miR-101 suppressed the expression of c-myc, CDK2, CDK4, CDK6, CCND2, CCND3, and CCNE2, while promoted tumor suppressor p14, p16, p21 and p27 expression. In clinical specimens, SOCS2 was over-expressed in tumors and H. pylori positive tissues and its mRNA levels were inversely correlated with miR-101 expression. Taken together, our results indicated that miR-101 functions as a growth-suppressive miRNA in H. pylori related GC, and that its suppressive effects are mediated mainly by repressing SOCS2 expression.     

Prospective study of Helicobacter pylori antigens and gastric noncardia cancer risk in the nutrition intervention trial cohort

Helicobacter pylori (H. pylori) infection is the strongest known risk factor for gastric noncardia adenocarcinoma (GNCA). We used multiplex serology to determine whether seropositivity to 15 H. pylori proteins is associated with the subsequent development of noncardia gastric cancer in Linxian, China. We included 448 GNCA cases and 1242 controls from two time points within the Linxian General Population Nutrition Intervention Trial, Linxian. H. pylori multiplex seropositivity was defined as positivity to ≥4 of the 15 included antigens. Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted for major GNCA risk factors. In addition, we undertook a meta‐analysis combining H. pylori multiplex serology data from both time points. H. pylori multiplex seropositivity was associated with a significant increase in risk of GNCA at one time point (1985; OR: 3.44, 95% CI: 1.91, 6.19) and this association remained significant following adjustment for H. pylori or CagA ELISA seropositivity (OR: 2.92, 95% CI: 1.56, 5.47). Combining data from both time points in a meta‐analysis H. pylori multiplex seropositivity was associated with an increased risk of GNCA, as were six individual antigens: GroEL, HP0305, CagA, VacA, HcpC and Omp. CagM was inversely associated with risk of GNCA. We identified six individual antigens that confer an increase in risk of GNCA within this population of high H. pylori seroprevalence, as well as a single antigen that may be inversely associated with GNCA risk. We further determined that the H. pylori multiplex assay provides additional information to the conventional ELISA methods on risk of GNCA.     

Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia

BACKGROUND: Helicobacter pylori-induced gastritis is an important factor for gastric carcinogenesis. However, it is still controversial whether it is also applicable for cardiac cancer development. Recently, we reported that H. pylori is an important factor for the induction of cardiac inflammation. We examined the status of H. pylori-induced gastritis in patients with cardiac cancer. METHODS: Seventy-five Japanese patients (58 men; mean age, 64.2 years) with cardiac cancer were studied. Cardiac cancer was defined as that mainly located within 2 cm from the squamo-columnar junction (SCJ). Histological gastritis including the cardiac region was evaluated using the biopsy or surgically resected sections. Cardiac inflammation was evaluated at 1 cm distal from SCJ in lesser curvature. Sera were collected and several markers were evaluated. The status of H. pylori infection was evaluated by histology and serum antibodies. Expressions of cytokeratins were examined by immunohistochemical analysis. RESULTS: Out of 75 patients with cardiac cancer, H. pylori was positive in 71 (95%) patients. The cardiac inflammation was examined in 30 patients (26 with H. pylori and four without H. pylori infection) and we found cardiac inflammation was present in all cases with H. pylori infection. Histologically, H. pylori-related gastritis was also found in the gastric corpus and antrum. Serological data were consistent with the presence of chronic atrophic gastritis. Intestinal metaplasia was found in 18 cases in the cardiac mucosa, and their cytokeratin 7/20 pattern was judged as a gastric pattern in all cases. CONCLUSION: H. pylori infection is closely associated with cardiac cancer.